Vera Therapeutics

Yahoo Finance • 3 months ago

Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Vera Therapeutics Inc. (NASDAQ:VERA) ranks among the best-performing small-cap stocks in 2024. The Case for Small Caps... Full story

Yahoo Finance • last year

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgAN Announced analysis of Phase 2b ORIGIN study showing reso... Full story

Yahoo Finance • last year

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients. Additional poster presentations provide further safety analysis of Phase 2b... Full story

Yahoo Finance • last year

Vera Therapeutics Scheduled to Present at November Investor Conferences

BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunol... Full story

Yahoo Finance • last year

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating ataciceptin IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potent... Full story

Yahoo Finance • last year

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk p... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN

BRISBANE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dis... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA

NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. (“Vera” or the “Company”) (NASDAQ: VERA). Such investors are advised to contact Robert S. Willoughby at n... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept i... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

BRISBANE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA

NEW YORK, Jan. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. (“Vera” or the “Company”) (NASDAQ: VERA).   Such investors are advised to contact Robert S. Willoughby at... Full story

Yahoo Finance • 2 years ago

These 2 Nasdaq Biotechs Are Making Big Moves Wednesday

The Nasdaq Composite (NASDAQINDEX: ^IXIC) tried to bounce back on Wednesday morning, seeking to recover losses from the first trading day of 2023. As of shortly after the opening bell, the Nasdaq had moved up by more than half a percent. I... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in protein... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics to Present at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological di... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy topline data planned to be presented in early Q1 2023 Initiated pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis Strong balance sheet with $114.4 million... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting

New analysis of Phase 2a JANUS clinical trial showed atacicept reduced immune complex levels in patients with IgA nephropathy (IgAN)Atacicept is the first therapeutic to show reduction in all of the three first hits of IgAN pathogenesis –... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics to Present at Upcoming Conferences in September 2022

BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological d... Full story